You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Dare to Compare: How Well Do You Know CLL?

  • Authors: Tristin D. Abair, PhD
  • CME / ABIM MOC / CE Released: 9/30/2022
  • Valid for credit through: 9/30/2023, 11:59 PM EST
Start Activity

Target Audience and Goal Statement

This activity is intended for hematologists/oncologists, pathologists, nurses, nurse practitioners, pharmacists, and other health specialists involved in the care of patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

The goal of this activity is for learners to be better able to provide optimal care for their patients with R/R CLL and self-assess their learning needs.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Current and emerging therapeutic options for their patients with R/R CLL
  • Self-assess learning needs related to
    • Optimizing treatment for patients with R/R CLL


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


  • Tristin D. Abair, PhD

    Senior Medical Writer
    Medscape, LLC


    Tristin D. Abair, PhD, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Accreditation Statements


Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Contact This Provider

    For Nurses

  • Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number: JA0007105-0000-22-338-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Dare to Compare: How Well Do You Know CLL?

Authors: Tristin D. Abair, PhDFaculty and Disclosures

CME / ABIM MOC / CE Released: 9/30/2022

Valid for credit through: 9/30/2023, 11:59 PM EST



  1. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology. Chronic lymphocytic leukemia/small lymphocytic lymphoma. Version 1.2022. Published August 30, 2022. Accessed September 6, 2022.
  2. Wierda WG, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study. J Clin Oncol. 2021;39:3853-3865.
  3. Hillmen P, et al. Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study. J Clin Oncol. 2019;37:2722-2729.
  4. Mato AR, et al. Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy. Clin Cancer Res. 2020;26:3589-3596. 
  5. Lin VS, et al. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. Blood. 2020;135:2266-2270.
  6. Mato AR, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103:874-879. 
  7. Hou JZ, et al. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia. Future Oncol. 2021;17:4959-4969.
  8. Hampel PJ, et al. Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib. Blood Cancer J. 2022;12:124.
  9. Bond DA, et al. Targeting BTK in CLL: beyond ibrutinib. Curr Hematol Malig Rep. 2019;14:197-205. 
  10. Jones JA, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19:65-75.
  11. Byrd JC, et al. First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia. Presented at: 2021 American Society of Clinical Oncology Annual Meeting Virtual; June 4-8, 2021. Presentation 7500.
  12. Hillmen P, et al. First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Presented at: European Hematology Association Virtual Congress; June 9-17, 2021. Presentation LB1900.
  13. Ibrutinib [prescribing information]. Approved 2013. Revised May 2022.
  14. Acalabrutinib [prescribing information]. Approved 2017. Revised March 2022.
  15. Jain P, et al. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer. 2017;123:2268-2273.
  16. Rogers KA, et al. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica. 2021;106:2364-2373.
  17. Awan FT, et al. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv. 2019;3:1553-1562.
  18. Shadman M, et al. Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib. Presented at: European Hematology Association Congress (EHA 2021); June 9-17, 2021; Virtual. Poster EP642.
  19. Zanubrutinib [prescribing information]. Approved 2019. Revised September 2021.
  20. Woyach JA, et al. Preliminary efficacy and safety of MK-1026, a non-covalent inhibitor of wild-type and C481S mutated Bruton tyrosine kinase, in B-cell malignancies: a phase 2 dose expansion study. Blood. 2021;138(suppl):392.
  21. Mato AR, et al. Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: updated results from the phase 1/2 BRUIN study. Blood. 2021;138(suppl):391.
  22. Woyach JA, et al. BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017;35:1437-1443.
  23. Zain R, et al. Structure-function relationships of covalent and non-covalent BTK inhibitors. Front Immunol. 2021;12:694853.
« Return to: Dare to Compare: How Well Do You Know CLL?
  • Print